UK markets open in 4 hours 41 minutes

Genmab A/S (GMABC.XC)

Cboe UK - Cboe UK Real-time price. Currency in DKK
Add to watchlist
1,954.250.00 (0.00%)
At close: 01:46PM BST
Full screen
Previous close1,954.25
Open1,954.25
Bid1,902.00 x 0
Ask1,934.00 x 0
Day's range1,954.25 - 1,954.25
52-week range1,918.00 - 2,798.00
Volume20
Avg. volume78
Market cap125.557B
Beta (5Y monthly)0.81
PE ratio (TTM)23.53
EPS (TTM)83.06
Earnings date01 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Transactions in Connection with Share Buy-back Program

    Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from June 3, 2024, to June 7, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announceme

  • Globe Newswire

    Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

    Media Release COPENHAGEN, Denmark; June 05, 2024Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida 9:20 AM EDT (3:20 PM CEST) on June 10, 2024. A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is

  • Business Wire

    Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

    COPENHAGEN, Denmark, June 03, 2024--Genmab A/S (Nasdaq: GMAB) announced today that data from the Phase 2 innovaTV 207 trial (NCT03485209) Part C (n=40), investigating tisotumab vedotin, an antibody-drug conjugate directed to tissue factor, demonstrated encouraging antitumor activity as a monotherapy in patients with head and neck squamous cell carcinoma (HNSCC) who experienced disease progression on or after first-line therapy. The study showed 32.5% of patients achieved a confirmed objective re